December 2, 2022
Healios, a Tokyo-based biotech, said on December 1 that it will supply Sumitomo Pharma with its universal donor cells (UDCs), or allogeneic iPS cells with a lower risk of immune rejection. The Osaka drug maker will research the potential use...read more